Abstract: The present invention provides a treating method for a solution containing rare earth, wherein the method comprising: (1) performing a fine-grained clay adsorption on the solution containing rare earth with fine-grained clay, the conditions of the fine-grained clay adsorption allow that solution adsorbed by said fine-grained clay contains rare earth with a concentration calculated by rare earth oxides not higher than 1 mg/L; (2) performing a coarse-grained clay adsorption on the solution adsorbed by said fine-grained clay with coarse-grained clay, the conditions of coarse-grained clay adsorption allow that solution adsorbed by said coarse-grained clay contains rare earth with a concentration calculated by rare earth oxides not higher than 0.

Abstract: The present invention provides a treating method for a solution containing rare earth, wherein the method comprising: (1) performing a fine-grained clay adsorption on the solution containing rare earth with fine-grained clay, the conditions of the fine-grained clay adsorption allow that solution adsorbed by said fine-grained clay contains rare earth with a concentration calculated by rare earth oxides not higher than 1 mg/L; (2) performing a coarse-grained clay adsorption on the solution adsorbed by said fine-grained clay with coarse-grained clay, the conditions of coarse-grained clay adsorption allow that solution adsorbed by said coarse-grained clay contains rare earth with a concentration calculated by rare earth oxides not higher than 0.

Abstract: An agent for imaging of a biological system or delivering drugs to a biological system including one or more nanoparticles formed of at least one gadolinium coordination polymer.

Abstract: An agent for imaging of a biological system or delivering drugs to a biological system including one or more nanoparticles formed of at least one gadolinium coordination polymer.

Abstract: Gadolinium+3 (Gd3+) containing (or incorporated) Prussian blue lattice contrast agents that can be used as an MRI contrast agent have unexpectedly improved r1 relaxivities of 1 or 2 magnitudes higher than the commercial Gd3+-chelates as well as exceedingly, non-toxic, low release of the Gd3+ ions into an aqueous environment at a pH of about 2 to about 7.5. The Prussian blue lattice containing Gd3+ ions therein can be used for clinical diagnosis intravenously to human beings for medical imaging. The particle sizes of the doped Prussian blue lattices are of a nanosize scale and are very stable against agglomeration.

Abstract: Gadolinium+3 (Gd3+) containing (or incorporated) Prussian blue lattice contrast agents that can be used as an MRI contrast agent have unexpectedly improved r1 relaxivities of 1 or 2 magnitudes higher than the commercial Gd3+-chelates as well as exceedingly, non-toxic, low release of the Gd3+ ions into an aqueous environment at a pH of about 2 to about 7.5. The Prussian blue lattice containing Gd3+ ions therein can be used for clinical diagnosis intravenously to human beings for medical imaging. The particle sizes of the doped Prussian blue lattices are of a nanosize scale and are very stable against agglomeration.